Summary To investigate the long-term survival rate of node-positive (pN+) breast cancer treated by locoregional therapy alone, we made an attempt to identify all such patients followed up for at least 15 years after treatment in a defined geographical area (city of Turku, Southwestern Finland) and time period 
Presence of axillary nodal metastases and the number of involved lymph nodes at diagnosis are well-established prognostic factors in breast cancer. The management of the axilla in early breast cancer is controversial (Sacks and Baum, 1993) . Axillary nodal dissection may cause morbidity, including post-operative seroma, upper-limb numbness, pain, restriction of shoulder movement and swelling of the arm. The need to perform axillary nodal dissection for assessment of prognosis has been questioned because valid prognostic information can be obtained by analysing clinical and biological factors of the primary tumour, by detecting micrometastases in the bone marrow (Harbeck et al, 1994) or by using the sentinel node biopsy technique (Giuliano et al, 1995) . Moreover, two large randomized trials have suggested that failure to treat involved axillary nodes is not associated with worse survival (Cancer Research Campaign Working Party, 1980; Fisher et al, 1985) , which has led to the hypothesis that metastatic axillary nodes are an expression rather than a determinant of a poor outcome. However, the results of two recently published randomized trials with a median follow-up of 9.5 and 12.5 years show that locoregional radiotherapy combined with adjuvant chemotherapy is superior to adjuvant chemotherapy alone in premenopausal node-positive patients treated with mastectomy (Overgaard et al, 1997; Ragaz et al, 1997) , suggesting that careful treatment of axillary nodal metastases is of great importance in the management of breast cancer.
There are a few reported series in which a subset of patients with node-positive breast cancer has been found to survive longer than 20 years after the diagnosis, suggesting that node-positive breast cancer may sometimes be a curable disease (Adair et al, 1974; Fentiman et al, 1984; Rutqvist et al, 1985; Rosen et al, 1989 ; Lee et al, 1992; Nab et al, 1994) . However, treatment given in these series has been variable, and the series may have included patients who received systemic treatments in addition to local therapy. Some of the studies are based on single-centre data, raising the possibility of patient selection. A systematic review of the histopathological data particularly concerning axillary nodal involvement by cancer may not have been performed, and often patients with a second primary breast cancer have been included in the analyses. Moreover, there are few data available on how to predict which patients, if any, with node-positive breast cancer might become long-term survivors. Hence, the long-term survival rate of patients with node-positive breast cancer treated with locoregional therapy only is difficult to assess based on the studies available, and there is uncertainty as to whether axillary nodal involvement by breast cancer should be considered as a conclusive sign of disseminated disease or not.
In the present study we have followed up practically all women with node-positive unilateral breast cancer diagnosed in a welldefined geographical area for a minimum of 15 years after diagnosis. All patients were treated with mastectomy and axillary nodal dissection without any adjuvant systemic therapy, and in all cases the diagnosis and axillary lymph node involvement was confirmed histologically. The results are compatible with the hypothesis that the presence of axillary nodal metastases at the time of the diagnosis is not a conclusive sign of disseminated breast cancer, and that such patients can sometimes be cured by locoregional therapy alone.
PATIENTS AND METHODS Patients
In order to identify all patients diagnosed with invasive breast cancer in the city of Turku, located in Southwestern Finland, the hospital records of the two hospitals in the city, the Turku University Central Hospital and the City Hospital of Turku, were examined. In addition, we searched the data obtained from the Finnish Cancer Registry, founded in 1952. Hospitals, practising physicians and pathological and haematological laboratories are requested to report all cases of cancer that come to their attention to the Finnish Cancer Registry. In addition, all death certificates in which cancer is mentioned are transferred from the files of the Statistics Finland to the Cancer Registry each year. After identifying the patients from these sources, we reviewed the hospital and autopsy case records and examined the histological and autopsy slides. We identified and confirmed the diagnosis of invasive breast cancer in 1172 female patients during the time period from 1945 to 1979. Based on the data obtained from the Finnish Cancer Registry and the local hospital files, we estimate that this is at least 94% of all cases diagnosed with breast cancer in the city during the time period. The time period 1945-79 was chosen because this would allow a minimum of 15-year follow-up for the patients still alive. According to a previous analysis performed by us (Joensuu and Toikkanen, 1995) and others (Hibberd et al, 1983; Nab et al, 1994) , few women with unilateral breast cancer die of the disease after the 15th year of follow-up.
The hospital and autopsy records, registry data and all histological material available on the 1172 patients were reviewed. After this, women with ductal cancer in situ (n = 37), those with distant metastases at presentation (n = 75) and those treated with a palliative intent only (n = 31) were excluded, as well as women who had synchronous or metachronous bilateral breast cancer (n = 72). From the remaining 957 patients we excluded all cases with node-negative disease (pNO, n = 450) and those who did not have axillary nodal dissection (n = 118). Fifty (12.9%) of the remaining 389 patients with unilateral, invasive, histopathologically nodepositive breast cancer treated with a curative intent had received some kind of systemic therapy (ovarian ablation, n = 41; tamoxifen or cytostatic drugs, n = 9). The 339 remaining patients who did not receive systemic adjuvant therapy form the basis of the study. All 339 patients have been followed up for at least 15 years or until death (median, 23 years; maximum, 41 years).
The median age at diagnosis was 56 years (range, 24-93). Clinical staging was performed according to the International Union Against Cancer tumour-node-metastasis (UICC TNM) classification (1992).
Therapy
The majority (76%) of the patients were treated with radical or modified radical mastectomy, and the rest with simple mastectomy combined with axillary nodal dissection. At least level I and II axillary nodes were usually removed. Most of the patients (84%) received post-operative locoregional radiotherapy, either with orthovoltage during the early study period (before 1973), or megavoltage irradiation in the 1970s. The ipsilateral axillary, supraclavicular, infraclavicular and parastemal nodes were usually irradiated. The chest wall has been systematically irradiated since 1973.
Histology
The original histological slides were reviewed by one pathologist very experienced in breast cancer pathology (ST). New haematoxylin and eosin (H&E-) stained slides were prepared, if necessary. Histological typing was performed according to the WHO classification (1981) , and the tumours were classified into the following three types: (1) infiltrating ductal carcinoma not otherwise specified (NOS; includes apocrine, mixed mucinous and atypical medullary types); (2) infiltrating lobular carcinoma with variants; and (3) other special types (includes tubular, medullary, cribriform, papillary and pure mucinous carcinomas). Grading was performed according to the WHO classification, and the grading of infiltrating lobular cancer was done by evaluating the degree of nuclear pleomorphism. The number of mitoses per high-power field (Leizt Orthoplan microscope, x 400 magnification) was counted as an average of ten fields.
In all 339 cases, the presence of breast cancer in axillary lymph nodes was confirmed histopathologically. Cases in which cancer was present outside the lymph node capsule were classified as pN2. There were no pN3 cases in the series because the parasternal lymph nodes were not removed at surgery. Supraclavicular metastatic lymph nodes were classified as Ml disease (UICC TNM classification, Hermanek and Sobin 1992). The number of lymph nodes involved could not be reliably extracted from the case records because the entire axillary content was not systematically investigated during the time period of the study.
Statistical methods
Statistical analyses were carried out with the BMDP computer program (BMDP Statistical Software, Department of Biomathematics, University of California, Los Angeles, CA, USA). Frequency tables were analysed with the chi-square test. The cumulative survival was estimated with the product-limit method and comparison of the cumulative survival rate between groups was performed with the log-rank test. Both overall (crude) survival rate and survival rate corrected for intercurrent deaths were calculated. When calculating the corrected survival rate, patients who died from causes other than breast cancer according to autopsy or clinical evidence were censored at the date of death. A patient was considered to have died from cancer if distant metastases confirmed by histology, cytology or imaging examinations were present at the time of her death. The relative survival rate was calculated by dividing the crude survival rate by the expected rate in the general female population, matched for age and year of observation. The expected survival rate was obtained from the tables of Statistics Finland and the Finnish Cancer Registry. The relative importance of prognostic factors was analysed with Cox's proportional hazard model (BMDP 2L). All P-values are two-tailed. corrected for intercurrent deaths were 26% (95% confidence interval, 21-31%) and 21% (16-26%) respectively. The relative survival obtained by dividing the overall survival rate by the expected survival rate in age-, sex-and year of observation-matched population resulted in a similar long-term survival estimate that was obtained by correcting for known intercurrent deaths by the clinical and autopsy data (Figure 1 ). The relative survival rate remained essentially the same after the first 15 years of follow-up with 21-23% of the patients remaining as long-term survivors (Table 1) .
None of the 35 patients with pN2 disease survived for 15 years after the diagnosis, whereas 19% (15-23%) of patients with pNl cancer were alive 15 years after the diagnosis and 9% (5-13%) 30 years after the diagnosis (P < 0.0001). When survival corrected for intercurrent diseases was analysed, it turned out that 29% (23-35%) of the patients with pN1 disease were 15-year survivors and 24% (18-30%) were estimated to be 30-year survivors (Figure 2 ). The 15-year survival rate corrected for intercurrent deaths was 57% (42-72%) among patients with pTINlMO (n = 43) or pTl N2MO (n = 3) disease and 59% (43-75%) among the 43 patients with pTINIMO disease (Figure 3) . Histological grade, the number of mitoses, presence of tumour necrosis, primary tumour size, axillary nodal status (pN2 vs pNl) and histological type were also significantly associated with corrected survival in a univariate analysis (Table 2) . When these six factors classified as in Table 2 were entered into a multivariate analysis, only histological grade (relative risk 1.7; 95% confidence interval, 1.4-2.1), primary tumour size (1.8, 1.5-2.2) and axillary nodal status (2.0, 1.4-3.0) had independent influence on corrected or overall survival (Table 3) .
When the series was divided into three cohorts based on the decade when the diagnosis was made, it turned out that survival rates were better in the 1960s and 1970s than in the 1940s and 1950s (P < 0.0001). The 15-year corrected survival rate found among women with pN+ disease diagnosed in the 1970s was 34% (25-43%) compared with 13% (6-20%) in the 1940s and 1950s (Table 4 ). The result remained essentially similar, if patients with pN2 disease were excluded from the analysis (P < 0.0001).
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DISCUSSION
In the present series a considerable proportion of breast cancer patients with histologically confirmed axillary nodal metastases at diagnosis were long-term survivors even if no systemic treatment was given. The series includes the great majority of patients diagnosed in a well-defined urban area, which precludes a major selection bias. Only a few deaths from ipsilateral breast cancer take place after the 15th year of follow-up in node-positive or nodenegative disease (Hibberd et al, 1983; Nab et al, 1994; Joensuu and Toikkanen, 1995) , and, therefore, it is unlikely that a longer follow-up would have changed the result of the study markedly. These data suggest that involvement of the axillary lymph nodes by cancer is not a conclusive sign of disseminated disease. Hypothetically, the patients who survive for decades after the diagnosis of breast cancer metastatic to the axillary lymph nodes might have dormant cancer cells and die from intercurrent diseases before they succumb to breast cancer. However, we observed no deaths from ipsilateral breast cancer after the 24th year of followup, and the relative survival was the same as that found in the general population after the 15th year of follow-up. Therefore, locoregional therapy is likely to be curative in a subset of patients with node-positive breast cancer.
It is worth noting that patients with a small primary tumour (pTIN 1 MO) had as favourable as 59% 15-year survival rate corrected for intercurrent deaths. This figure is in line with that found by Rosen et al (1989) , who estimated that 52% of patients (Tables 2 and 3 ), none of the factors could identify a subset of patients with particularly favourable survival. Hence, adjuvant systemic therapy should probably be recommended to all patients with pN+ disease, because there is currently no reliable way to identify patients who might be cured without adjuvant therapy. However, the newer prognostic factors should be tested for this purpose.
In a randomized Danish study consisting of more than 1700 premenopausal patients with stage II or III breast cancer radiotherapy to the chest wall and the regional lymph nodes was found not only to reduce the frequency of locoregional relapses from 32% to 9%, but to increase significantly both disease-free and overall survival compared with patients who were treated with mastectomy and adjuvant chemotherapy alone (Overgaard et al, 1997) . Similar results were also obtained in a randomized Canadian study (Ragaz et al, 1997) . Both of these studies suggest that recurrent locoregional cancer may give rise to distant metas-tases in addition to the primary cancer, and that irradiation of the subclinical locoregional lymph node and chest wall metastases improves survival. These data also support the hypothesis that node-positive breast cancer has not always given rise to distant metastases, and that careful management of the regional lymph node regions is beneficial. Coupled with the present data, data from these randomized trials suggest that adequate locoregional therapy can cure many women with node-positive breast cancer.
We found better survival among the patients diagnosed in the 1960s and 1 970s compared with those diagnosed earlier. The reasons for this remain speculative, but improved survival with time might in part be explained by reduction in breast cancer size and less extensive axillary nodal involvement in the 1970s compared with the 1940s and 1950s. However, improvements in surgical and radiotherapy techniques may also play a role. Modern locoregional radiotherapy improves survival in node-positive breast cancer, and orthovoltage and cobalt therapy used in the city in the 1 940s to 1 960s may have been inferior to radiotherapy given with linear accelerators in the 1970s. The rate of axillary nodal dissection did not increase consistently during the study period in the city (83%, 77% and 90% of patients had axillary nodal dissection in 1945-59, 1960-69 and 1970-79 respectively) . Breast cancer, per se, might also have become less aggressive with time, but we consider this unlikely. When a few biological and histological prognostic factors were compared between breast cancers diagnosed in the city in the 1 980s and those diagnosed in the 1 940s to 1960s adjusting for the generally smaller size of the cancers diagnosed in the 1980s, little change in the malignancy grade with time could be found (Joensuu and Toikkanen, 1991) .
In conclusion, the present results suggest that a subgroup of women with axillary nodal metastases from ipsilateral breast cancer are permanently cured by locoregional therapy alone. Therefore, axillary nodal involvement is not a conclusive sign of disseminated disease. Furthermore, the time trends in the study cohort suggest that the long-term survival rate of 24% among patients with pN1 disease and treated with locoregional therapy is a conservative estimate. The present results combined with those of recently published randomized trials suggest that careful locoregional treatment is mandatory in the care of node-positive breast cancer in addition to systemic therapy.
